Ultragenyx Agrees to Sell Priority Review Voucher for $210 Million

Ultragenyx has agreed to sell its Rare Pediatric Disease Priority Review Voucher for $210 million, the company said October 7, 2026. The voucher lets its holder move a future application to the FDA, the US drug regulator, onto a priority review timeline. This is an agreement, not a completed transfer. Sale proceeds would be cash raised without issuing new shares.